TIDMPRTC
RNS Number : 0857N
PureTech Health PLC
27 January 2016
PureTech Expands Scientific Advisory Board and Appoints New
Senior Advisors
Edward Boyden, David A. Edwards, Donald E. Ingber, Sachin H.
Jain and Robert J. Perez Join Company's Advisory Group of Over 50
Leading Scientists and Clinicians
Boston, Massachusetts, January 27, 2016 - PureTech Health plc
("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary
healthcare company developing novel medicines to tackle fundamental
healthcare needs in disruptive ways, today announced it has
expanded its Scientific Advisory Board ("SAB") and appointed new
Senior Advisors to the Company.
Edward Boyden, Ph.D., optogenetics pioneer, professor of
Biological Engineering and Brain and Cognitive Sciences at the
Massachusetts Institute of Technology (MIT) Media Lab and the MIT
McGovern Institute, has been appointed to PureTech's SAB, David A.
Edwards, Ph.D., the Gordon McKay Professor of the Practice of Idea
Translation at the Harvard John A. Paulson School of Engineering
and Applied Sciences, Donald E. Ingber, M.D., Ph.D., Founding
Director of the Wyss Institute for Biologically Inspired
Engineering at Harvard University, Sachin H. Jain, M.D., Chief
Operating Officer and Chief Medical Officer of CareMore Health and
former Chief Medical Information and Innovation Officer at Merck,
and Robert J. Perez, former Chief Executive Officer of Cubist, have
been appointed Senior Advisors to the Company.
"Our new advisors are visionaries in their fields and bring
world-class experience to PureTech's growing advisory network of
distinguished scientists and clinicians," said Daphne Zohar, Chief
Executive Officer of PureTech Health. "We are delighted to welcome
them to our team, and look forward to their guidance as we pursue
innovations in science and technology that have the potential to
change how we address today's healthcare challenges."
Newly Appointed PureTech Advisors
Dr. Boyden will join PureTech as a member of the Company's SAB.
He is a professor of Biological Engineering and Brain and Cognitive
Sciences at the MIT Media Lab and the MIT McGovern Institute. He
leads the Synthetic Neurobiology Group, which has invented a suite
of "optogenetic" tools that are now in use by thousands of research
groups around the world for activating and silencing neurons with
light. Dr. Boyden received the Breakthrough Prize in Life Sciences
(2016), the Society for Neuroscience Young Investigator Award
(2015), the Carnegie Prize in Mind and Brain Sciences (2015), the
Schuetze Prize (2014), the Jacob Heskel Gabbay Award (2013), the
Grete Lundbeck Brain Prize (2013), the NIH Director's Pioneer Award
(2013), the NIH Director's Transformative Research Award (twice,
2012 and 2013) and the Perl/UNC Neuroscience Prize (2011). He was
also named to the World Economic Forum Young Scientist list (2013),
the Wired Smart List "50 People Who Will Change the World" (2012),
the Technology Review World's "Top 35 Innovators under Age 35" list
(2006), and his work was included in Nature Methods "Method of the
Year" in 2010. Dr. Boyden received his Ph.D. in neurosciences from
Stanford University as a Hertz Fellow and received degrees in
electrical engineering, computer science and physics from MIT. He
has contributed to over 300 peer-reviewed papers, current or
pending patents, and articles and has given over 300 invited talks
on his group's work.
Dr. Edwards is the Professor of the Practice of Idea Translation
at the Harvard John A. Paulson School of Engineering and Applied
Sciences, Founding Core Faculty Member of the Wyss Institute for
Biologically Inspired Engineering at Harvard University, Founder of
the creative center Le Laboratoire in Paris, France and Cambridge,
Massachusetts and founder of the future-of-food restaurant Café
ArtScience in Cambridge. Dr. Edwards is the founder of the drug and
vaccine delivery companies Advanced Inhalation Research (AIR), sold
to Alkermes, Pulmatrix and Medicine in Need. He has also founded
multiple companies aimed at the interface of multiple disciplines,
including Vapor Communications focused on digitising scent and
edible packaging company Quantum Designs. Dr. Edwards is a member
of the American and French National Academies of Engineering and
the National Academy of Inventors. He has received numerous
national and international awards for his creative work. In 2008,
he was made a Chevalier des Arts et des Lettres by the French
Ministry of Culture.
Dr. Ingber is the Founding Director of the Wyss Institute for
Biologically Inspired Engineering at Harvard University, the Judah
Folkman Professor of Vascular Biology at Harvard Medical School and
Boston Children's Hospital, and Professor of Bioengineering at the
Harvard John A. Paulson School of Engineering and Applied Sciences.
Dr. Ingber's work has catalysed the convergence of far-reaching
disciplines not previously connected, ranging from biology,
medicine, engineering, computer science and physics to art,
architecture and design, and his efforts contributed to the
emergence of the field of biologically inspired engineering. In
addition, Dr. Ingber has made major contributions to understanding
cell structure, mechanobiology, tissue engineering, tumour
angiogenesis, systems biology, nanobiotechnology, medical devices
and translational medicine. He has received numerous honors across
a broad range of disciplines, including the Holst Medal, Department
of Defense Breast Cancer Innovator Award, Pritzker Award from the
Biomedical Engineering Society, Rous-Whipple Award from the
American Society for Investigative Pathology, Lifetime Achievement
Award from the Society of In Vitro Biology, Leading Edge Award from
the Society of Toxicology, NC3Rs Award and the 2015 Design of the
Year Award. Dr. Ingber is also an honorary member of the Society of
Toxicology and a fellow of the American Institute for Medical and
Biological Engineering, National Academy of Inventors and the
National Academy of Medicine (formerly Institute of Medicine). He
has more than 125 patents and founded multiple companies, including
Emulate, Inc. and Opsonix, Inc. Dr. Ingber received his B.A., M.A.,
M.Phil., M.D. and Ph.D. from Yale University.
Dr. Jain is Chief Operating Officer and Chief Medical Officer at
CareMore Health System, an innovative health plan and care delivery
system subsidiary of Anthem, Inc. with $1.2 billion revenue and
over 100,000 members. In this role, he has operational
responsibility for 700 clinical and network staff. He is charged
with developing and leading a multi-year strategy to expand
next-generation Medicare and Medicaid care management/care delivery
model nationally. Prior to joining CareMore, Dr. Jain was Chief
Medical Information and Innovation Officer at Merck and Co., where
he developed global partnerships to leverage health data to improve
patient health. He also served as an attending hospitalist
physician at the Boston VA-Boston Medical Center and lecturer in
healthcare policy at Harvard Medical School. From 2009-2011, Dr.
Jain was a senior advisor to the administrator of the Centers for
Medicare & Medicaid Services (CMS) and helped to launch the
Center for Medicare and Medicaid Innovation (CMMI). He also served
as special assistant to the National Coordinator for Health
Information Technology at the Office of the National Coordinator
for Health Information Technology (ONC), supporting the agency's
implementation of the HITECH Provisions of the Recovery Act and
meaningful use. Dr. Jain graduated magna cum laude from Harvard
College with a B.A. in government, and continued on to earn his
M.D. from Harvard Medical School and an M.B.A. from Harvard
Business School. He is board certified in internal medicine by the
American Board of Internal Medicine. He is co-founder and
co-editor-in-chief of the Elsevier journal, Healthcare: The Journal
of Delivery Science and Innovation.
Mr. Perez is the former Chief Executive Officer of Cubist
(acquired by Merck for $9.5 billion), and has nearly 30 years of
experience in the biotechnology industry with a focus on
commercialising novel medicines. Prior to his role as CEO, Mr.
Perez served in various leadership roles at Cubist, including
Executive Vice President and Chief Operating Officer. During his
tenure, Mr. Perez built the company's novel commercial
infrastructure and led the launch of its blockbuster antibiotic,
Cubicin(R). Prior to joining Cubist, he served as Vice President of
Biogen, Inc.'s CNS Business Unit where he was responsible for
commercial leadership of an $800 million neurology business unit
and before that, held positions of increasing responsibility within
the commercial organisation. He also held various sales and
marketing positions at Zeneca Pharmaceuticals. Mr. Perez is a
member of the Board of Trustees of the Dana-Farber Cancer
Institute, Inc., the Board of Advisors of the Citizen School of
Massachusetts and a Board member of the Biomedical Science Careers
Program aimed at increasing the quality of a diverse workforce for
the life sciences. Mr. Perez received a B.S. in business from
California State University, Los Angeles, and an M.B.A. from the
Anderson Graduate School of Management at the University of
California, Los Angeles.
About PureTech's Scientific Advisory Board
(MORE TO FOLLOW) Dow Jones Newswires
January 27, 2016 04:00 ET (09:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024